A $3.2 million grant from the NIH will support the creation of Melanoma Resistance Evolution Atlas (MREA). Ultimately, researchers hope to develop novel approaches to prevention and treatment of resistant melanomas. Led by Dr. Roger Lo, professor of medicine and...
The FDA has approved a new botulinum toxin formulation for aesthetic use in the US. Letybo from Hugel America, Inc., a division of Hugel Inc., is approved to treat moderate-to-severe glabellar (frown) lines in adults. Letybo (letibotulinumtoxinA-wlbg) is expected to...
Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
A new, topical small molecule drug candidate shows promise for the treatment of androgenetic alopecia, having performed well in phase 2a clinical trials. TDM-105795 from Technoderma Medicines, Inc. is potent thyromimetic that has poor systemic absorption following...
The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Ycanth™, which is the only FDA-approved treatment for molluscum contagiosum. Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for Ycanth...